GEN Exclusives

More »

GEN Poll

Jul 17, 2012

Biopharma Job Outlook

The biopharma industry recently hit a rough patch with several major companies laying off workers. Roche is shutting down its Nutley, NJ, R&D site and planning to eliminate 1,000 jobs by the end of 2013. Novartis is planning to cut about 2,000 jobs nationwide, on top of 2,000 earlier European job cuts. AstraZeneca, Abbott, Takeda, Merck Serono, and Pfizer are also planning to lay off workers. However, there are possible silver linings: smaller biopharmas are expected to grow, and big pharma companies are beginning to hire new staff to cover areas left underserviced. So, how do you feel about your job stability right now?

Do you think the rough patch the biopharma industry is going through will affect your job stability?

Not at all
Somewhat Likely
Very Likely
It Already Has

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »